Latest News

This approach will help ensure that the local manufacturing of diagnostic imaging equipment remains economically viable and financially sustainable over the coming years.

Amgen’s latest acquisition is centered on Dark Blue’s lead candidate, DBT 3757, which specifically treats acute myeloid leukemia that affects bone marrow and blood cells.

Dr. Kays, who previously served JOOTRH as an obstetrician-gynecologist, returns after completing two years of specialized training in maternal-fetal medicine.

With a capacity exceeding 300 beds, the hospital will deliver both primary and secondary healthcare services to citizens and residents throughout the wilayat and surrounding areas.

Antimicrobial resistance (AMR) develops when bacteria, viruses, and fungi evolve to resist medications, making infections harder to treat and increasing the risk of severe illness and death.

Sanofi will leverage Earendil’s artificial intelligence (AI)-powered drug discovery platform to support the design and development of multiple new therapeutic assets.

The collaboration aimed to support the distribution of Valneva’s single-dose vaccine, Ixchiq, in low- and middle-income countries (LMICs) across Asia.

Through this agreement, Sanofi will gain full ownership of Heplisav-B, a two-dose hepatitis B vaccine that received US approval in 2017 and European authorization in 2021.

Before this partnership, JOOTRH referred radiotherapy cases to Kenyatta National Hospital (KNH) or Moi Teaching and Referral Hospital (MTRH).

Phenylketonuria (PKU) affects approximately one in 23,930 newborns globally, with higher prevalence in parts of Europe and the Middle East.